The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Sunitinib Rowex 12.5 mg hard capsules



Rowex LtdPA0711/289/001

Main Information

Trade NameSunitinib Rowex 12.5 mg hard capsules
Active SubstancesSunitinib
Dosage FormCapsule, hard
Licence HolderRowex Ltd
Licence NumberPA0711/289/001

Group Information

ATC CodeL01XE Protein kinase inhibitors
L01XE04 sunitinib

Status

License statusAuthorised
Licence Issued03/05/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Summary of Product Characteristics, section 4.2).
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable ListSunitinib 12.5mg Capsules
Interchangeable List CodeIC0147-021-001
Interchangeable List DocumentPDF of Interchangeable List
« Back